Hyalinosis infantile systemicalE78.9

Last updated on: 09.04.2022

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Infantile systemic hyalinosis(hyaline fibromatosis syndrome) is an autosomal recessive inherited disorder characterized by abnormal growth of hyalinized fibrous tissue.

ManifestationThis section has been translated automatically.

Initial manifestations occur in infancy and have additional visceral or systemic involvement, which can lead to early death. Accompanying symptoms are persistent diarrhea and increased susceptibility to infection. The massive nodular changes do not develop in this form.

LocalizationThis section has been translated automatically.

The disease mainly affects the subcutaneous regions of the scalp, ears, neck, face, hands and feet. The face, knees and elbows are particularly frequently affected. In many cases, gingival hyperplasia is detectable.

Note(s)This section has been translated automatically.

It is difficult to classify infants or young children with a "hyaline fibromatosis syndrome" into an infantile or juvenile form. Infantile systemic hyalinosis is classified as a particularly severe variant of juvenile hyaline fibromatosis (for further discussion, see there). In this respect, some authors use the term "hyaline fibromatosis syndrome (HFS)" for both variants. Denadai et al (2012) proposed a 4-level classification system of the disease to reflect increasing severity, with grade 4 leading to early death due to severe clinical decompensation.

LiteratureThis section has been translated automatically.

  1. Casas-Alba D et al (2018) Hyaline fibromatosis syndrome: clinical update and phenotype-genotype correlations. Hum Mutat 39:1752-1763.
  2. Chaudhry C et al (2021) Novel variation in ANTXR2 gene causing hyaline fibromatosis syndrome: A report from India. Congenit Anom (Kyoto) 61:140-141.
  3. Denadai, R et al. (2012) Identification of 2 novel ANTXR2 mutations in patients with hyaline fibromatosis syndrome and proposal of a modified grading system. Am J Med Genet 158A: 732-742.
  4. Dowling O et al (2003) Mutations in capillary morphogenesis gene-2 result in the allelic disorders juvenile hyaline fibromatosis and infantile systemic hyalinosis. Am J Hum Genet 73: 957-966.
  5. El-Kamah GY et al (2010) Spectrum of mutations in the ANTXR2 (CMG2) gene in infantile systemic hyalinosis and juvenile hyaline fibromatosis. (Letter) Brit. J. Derm. 163: 213-215.
  6. Härter B et al. (2020) Clinical aspects of hyaline fibromatosis syndrome and identification of a novel mutation. Mol Genet Genomic Med 8: e1203.
  7. KitanoY et al. (1972) Two cases of juvenile hyaline fibromatosis: some histological, electron microscopic, and tissue culture observations. Arch Derm 106: 877-883.
  8. Rahman N et al (2002) The gene for juvenile hyaline fibromatosis maps to chromosome 4q21. Am J Hum Gene 71: 975-980.

Last updated on: 09.04.2022